Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy.
Manon LevêqueNadim CassirFanny MathiasCindy FevreFlorence DavietJulien BermudezGeoffrey BrioudeFlorence PeyronMartine Reynaud-GaubertBenjamin CoiffardPublished in: Infection and drug resistance (2023)
Recipients transplanted for bronchiectasis in the context of a primary immune deficiency, such as common variable immunodeficiency, are at a high risk of severe infection in post-transplantation leading to poorer long-term outcomes than other transplant indications. In this report, we present a fatal case due to chronic Pseudomonas aeruginosa bronchopulmonary infection in a lung transplant recipient with common variable immunodeficiency despite successful eradication of an extensively drug-resistant (XDR) strain with IgM/IgA-enriched immunoglobulins and bacteriophage therapy. The fatal evolution despite a drastic adaptation of the immunosuppressive regimen and the maximal antibiotic therapy strategy raises the question of the contraindication of lung transplantation in such a context of primary immunodeficiency.
Keyphrases
- drug resistant
- pseudomonas aeruginosa
- multidrug resistant
- acinetobacter baumannii
- cystic fibrosis
- extracorporeal membrane oxygenation
- heart rate
- resistance training
- cell therapy
- stem cells
- biofilm formation
- early onset
- staphylococcus aureus
- blood pressure
- escherichia coli
- bone marrow
- helicobacter pylori
- combination therapy
- candida albicans
- kidney transplantation